LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer

ABSTRACT: This phase Ib/II trial investigates the side effects and best dose of LY3214996 when given together with cetuximab alone or in combination with abemaciclib and to see how well they work in treating patients with colorectal cancer that cannot be removed by surgery (unresectable) and/or has spread to other places in the body (metastatic). Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. LY3214996 and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving LY3214996 and cetuximab alone or in combination with abemaciclib may help treat patients with colorectal cancer.

DISEASE(S): Adenocarcinoma,Stage Iva Colorectal Cancer Ajcc V8,Stage Ivb Rectal Cancer Ajcc V8,Stage Iiib Colon Cancer Ajcc V8,Carcinoma,Metastatic Colorectal Carcinoma,Stage Iv Rectal Cancer Ajcc V8,Stage Iiic Rectal Cancer Ajcc V8,Stage Iii Colon Cancer Ajcc V8,Stage Iiic Colorectal Cancer Ajcc V8,Metastatic Colon Adenocarcinoma,Stage Ivc Rectal Cancer Ajcc V8,Stage Ivb Colorectal Cancer Ajcc V8,Stage Iv Colon Cancer Ajcc V8,Stage Iiib Rectal Cancer Ajcc V8,Stage Iiia Colon Cancer Ajcc V8,Unresectable Colon Adenocarcinoma,Colorectal Neoplasms,Stage Iva Colon Cancer Ajcc V8,Stage Ivc Colon Cancer Ajcc V8,Stage Iiic Colon Cancer Ajcc V8,Stage Iiib Colorectal Cancer Ajcc V8,Stage Ivc Colorectal Cancer Ajcc V8,Unresectable Colorectal Carcinoma,Stage Iv Colorectal Cancer Ajcc V8,Recurrent Colorectal Carcinoma,Metastatic Rectal Adenocarcinoma,Stage Iiia Colorectal Cancer Ajcc V8,Stage Iiia Rectal Cancer Ajcc V8,Stage Ivb Colon Cancer Ajcc V8,Unresectable Rectal Adenocarcinoma,Stage Iva Rectal Cancer Ajcc V8,Rectal Neoplasms,Stage Iii Rectal Cancer Ajcc V8,Stage Iii Colorectal Cancer Ajcc V8,Colonic Neoplasms

PROVIDER: 2356732 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR